| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 03/19/2002 | US6358963 For therapy of viral infections |
| 03/19/2002 | US6358952 Combination of benzoquinazoline antifolates and protecting agents |
| 03/19/2002 | US6358944 Methods and compositions for treating generalized anxiety disorder |
| 03/19/2002 | US6358923 Preventing and diagnosing blood, genetic, and nervous system disorders associated with decreased genetic expression |
| 03/19/2002 | US6358707 Polynucleotide sequences coding polypeptide associated with cellular secretion; for use in treatment of diabetes, stroke, atherosclerosis, restenosis, thrombosis, autoimmune disease, psoriasis, arthritis, crohn's, and inflammatory defects |
| 03/19/2002 | US6358706 Nucleotide sequences coding membrane protein; for use in treatment of epilepsy, schizophrenia, depression, sleep, stress, muscle, endocrine, respiratory, fertility, contraceptive, cardiovascular disorders and atherosclerosis |
| 03/19/2002 | US6358539 To supplement collagen and elastic tissues and thicken the dermis to reduce or eliminate the appearance of cellulite |
| 03/19/2002 | US6358536 Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal |
| 03/19/2002 | US6358526 Forming a compactable granular mixture comprising compaction enhancing therapeutic compound that is different from compaction enhancing therapeutic compound and non-aesthetic excipients; compressing the granular mixture to form tablets |
| 03/19/2002 | US6358522 For reducing anal leakage of oil in a patient to whom orlistat is being administered |
| 03/19/2002 | US6358513 Local administration of a therapeutically effective amount of a botulinum toxin to a patient, thereby increasing secretion of thyroid hormone, and ameliorating severity of hashimoto's thyroiditis for between two months to six months |
| 03/19/2002 | US6358443 Directing microdroplets into freezing section containing a liquefied gas; contacting frozen microdroplets in extraction section with liquid non-solvent to extract solvent into non-solvent to form microparticles |
| 03/19/2002 | CA2241981C Method of inhibiting photoaging of skin |
| 03/19/2002 | CA2193384C Use of gabapentin in the treatment of anxiety and panic |
| 03/15/2002 | CA2357155A1 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| 03/14/2002 | WO2002020849A2 Gene markers useful for detecting skin damage in response to ultraviolet radiation |
| 03/14/2002 | WO2002020846A2 Screening methods to identify compounds that modulate a response of a cell to ultraviolet radiation exposure |
| 03/14/2002 | WO2002020841A2 5-hydroxytryptamine receptor gene polymorphisms and response to treatment |
| 03/14/2002 | WO2002020822A2 Biopanning and rapid analysis of selective interactive ligands (brasil) |
| 03/14/2002 | WO2002020788A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 03/14/2002 | WO2002020769A1 Human and mouse targeting peptides identified by phage display |
| 03/14/2002 | WO2002020768A2 Caveolin peptides and their use as therapeutics |
| 03/14/2002 | WO2002020767A2 G-csf analog compositions and methods |
| 03/14/2002 | WO2002020766A2 G-csf analog compositions and methods |
| 03/14/2002 | WO2002020764A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 03/14/2002 | WO2002020763A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 03/14/2002 | WO2002020757A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 03/14/2002 | WO2002020736A2 Proteases |
| 03/14/2002 | WO2002020724A2 Adenoviral targeting and manipulation of immune system response using targeting peptides |
| 03/14/2002 | WO2002020723A2 Compositions and methods for targeting peptides in humans in vivo |
| 03/14/2002 | WO2002020722A2 Methods and compositions for in vitro targeting |
| 03/14/2002 | WO2002020718A2 Osteoclast-associated receptor |
| 03/14/2002 | WO2002020619A2 HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3) |
| 03/14/2002 | WO2002020617A1 The identification and development of specific monoclonal antibodies to squamous cell carcinoma |
| 03/14/2002 | WO2002020615A2 Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders |
| 03/14/2002 | WO2002020570A2 Mitochondrial membrane permeabilization bv hiv-1 vpr and methods of screening |
| 03/14/2002 | WO2002020560A1 Novel human cancer/testis antigen and gene thereof |
| 03/14/2002 | WO2002020524A1 Oxindole derivatives |
| 03/14/2002 | WO2002020514A1 Multivalent neuraminidase inhibitor conjugates |
| 03/14/2002 | WO2002020500A2 Materials and methods to potentiate cancer treatment |
| 03/14/2002 | WO2002020488A2 Quinoline and quinazoline derivatives as ligands for the neuropeptide y receptor |
| 03/14/2002 | WO2002020486A2 Picolinic acid derivatives for the prevention and treatment of cancer in animals |
| 03/14/2002 | WO2002020478A1 N-benzylindole-3-acetic acid derivatives for use in the treatment of drug resistan cancer |
| 03/14/2002 | WO2002020466A1 Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents |
| 03/14/2002 | WO2002020435A2 Generation of combinatorial libraries and assessment thereof by deconvolution |
| 03/14/2002 | WO2002020056A2 Methods and compositions for producing a neurosalutary effect in a subject |
| 03/14/2002 | WO2002020035A1 Hla binding peptides and their uses |
| 03/14/2002 | WO2002020026A2 Treatment of drug resistant organisms with nitric oxide |
| 03/14/2002 | WO2002020023A1 Methods and compositions for potentiating cancer chemotherapeutic agents |
| 03/14/2002 | WO2002020022A1 Method of treating neurologic disorders |
| 03/14/2002 | WO2002020020A1 Exemestane as chemopreventing agent |
| 03/14/2002 | WO2002020016A1 AGENT FOR MODULATING EXCITATORY SYNAPTIC TRANSMISSION COMPRISING A COMPOUND HAVING ALPHA α7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATION PROPERTY |
| 03/14/2002 | WO2002020003A2 Use of carp inhibitors for the treatment of heart diseases |
| 03/14/2002 | WO2002020002A2 A method for treating allergies |
| 03/14/2002 | WO2002019999A2 Compositions for treating sexual dysfunction, containing an no-donor and an antioxidant |
| 03/14/2002 | WO2002019996A2 Prevention of acute sinusitis and sinus attack |
| 03/14/2002 | WO2002019990A1 Modified release formulation |
| 03/14/2002 | WO2002019985A2 Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure |
| 03/14/2002 | WO2002019982A2 Cosmetic composition and method for reducing or preventing wrinkling |
| 03/14/2002 | WO2002019981A2 Cosmetic and pharmaceutical composition comprising chelating/sequestering agents and their cosmetic and dermatological use |
| 03/14/2002 | WO2002019812A2 Mutant non-human mammal for expressing the alpha6 acetylcholine nicotinic receptor subunit and use for screening substances capable of interacting with said receptor |
| 03/14/2002 | WO2001090189A3 G-protein coupled receptor org3. |
| 03/14/2002 | WO2001079502A3 Vectors for gene therapy |
| 03/14/2002 | WO2001078696A3 Formulations for use in inhaler devices |
| 03/14/2002 | WO2001078651A3 Method for treating neoplasmin with topoisomase i inhibitor |
| 03/14/2002 | WO2001077147A3 New bromodomain protein |
| 03/14/2002 | WO2001074790A3 Novel compounds for enhancing chemotherapy |
| 03/14/2002 | WO2001072290A3 Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
| 03/14/2002 | WO2001070768A3 Receptor-binding compounds and method for identifying them |
| 03/14/2002 | WO2001070757A3 Thioketals and thioethers for inhibiting the expression of vcam-1 |
| 03/14/2002 | WO2001066081A3 Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients |
| 03/14/2002 | WO2001061007A3 Fibroblast growth factor-23 molecules and uses thereof |
| 03/14/2002 | WO2001060396A3 Method for treating thyroid disorders |
| 03/14/2002 | WO2001058918A3 Oligonucleotides modulating the expression of enzymes involved in the synthesis of melanic pigments |
| 03/14/2002 | WO2001057085A3 G-protein coupled receptors |
| 03/14/2002 | WO2001055392A3 Nuclear hormone receptors |
| 03/14/2002 | WO2001055358A3 Phosphodiesterases |
| 03/14/2002 | WO2001054707A3 Modification of surface proteins by aminopeptidase inhibitors |
| 03/14/2002 | WO2001054659A3 Slimming cosmetic composition comprising a plant extract containing a plant natriuretic peptide (pnp) |
| 03/14/2002 | WO2001051519A3 Potassium channel mutants of the saccharomyces cerevisiae yeast and the use thereof for the screening of eukaryotic potassium channels |
| 03/14/2002 | WO2001045715A3 Combinations of an adenosine a1 agonist with an opioid and their use in the treatment of pain |
| 03/14/2002 | WO2001045684A3 Formulations of adenosine a1 agonists |
| 03/14/2002 | WO2001045683A3 Formulations of adenosine a1 agonists |
| 03/14/2002 | WO2001045682A3 Formulations of adenosine a1 agonists |
| 03/14/2002 | WO2001044497A3 Protein kinase regulation |
| 03/14/2002 | WO2001036684A3 Mammalian toxicological response markers |
| 03/14/2002 | WO2001032161A3 Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders |
| 03/14/2002 | WO2001032130A3 Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
| 03/14/2002 | WO2001021651A3 Novel human protease inhibitor-like proteins and polynucleotides encoding the same |
| 03/14/2002 | WO2001021194A3 Method for the therapeutic management of endometriosis and fallopian tube obstruction |
| 03/14/2002 | WO2001020031A3 Polymorphisms in a klotho gene |
| 03/14/2002 | WO2000074662A3 Arthritis treatment |
| 03/14/2002 | WO2000063441A3 Single nucleotide polymorphisms in mitochondrial genes that segregate with alzheimer's disease |
| 03/14/2002 | WO2000056899A9 Dsp-2 dual-specificity map kinase phosphatase |
| 03/14/2002 | WO2000053742A9 Polynucleotides and proteins encoded thereby |
| 03/14/2002 | WO1997003998A9 Modulators of the function of fas receptors and other proteins |
| 03/14/2002 | US20020032464 Adhesion prevention and an endoscopic insufflation system therefor |
| 03/14/2002 | US20020032234 First fatty acid compound that is a linoleic or linolenic compound and a second fatty acid that is a docosahexaenoic acid compound, an omega-3 or an omega-2 fatty acid or derivative |
| 03/14/2002 | US20020032224 Treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system disorders |
| 03/14/2002 | US20020032219 Use of alpha-1c specific compounds to treat benign prostatic hyperplasia |